Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy for bladder cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The primary role of immunotherapy for bladder cancer is to treat superficial transitional cell carcinomas (ie, carcinoma in situ, Ta, and T1). Immunotherapy in the form of bacille Calmette-Guérin (BCG), interferon, bropirimine, keyhole limpet hemocyanin, and gene therapy is intended to treat existing or residual tumor, to prevent recurrence of tumor, to prevent progression of disease, and to prolong survival of patients. Presently, BCG is commonly used and is the most effective immunotherapeutic agent against superficial transitional cell carcinoma. Data support that BCG has a positive impact on tumor recurrence, disease progression, and survival. Proper attention to maintenance schedules, route of administration, dosing, strains, and viability is essential to obtain the maximum benefits of BCG immunotherapy. This review highlights and summarizes the recent advances concerning immunotherapy, with special emphasis on BCG therapy for transitional cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ro JY, Staerkel GA, Ayala Ag: Cytologic and histologic features of superficial bladder cancer (review). J Urol Clin North Am 1992, 19:435–449.

    CAS  Google Scholar 

  2. Heney NM, Ahmed S, Flanagan MJ, et al.: Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083–1086.

    PubMed  CAS  Google Scholar 

  3. Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997, 80:762–765.

    PubMed  CAS  Google Scholar 

  4. Vicente J, Laguna MP, Duarte D, et al.: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 1991, 68:380–382.

    PubMed  CAS  Google Scholar 

  5. Abel PD: Follow-up of patients with “superficial” transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993, 72:135–142.

    Article  PubMed  CAS  Google Scholar 

  6. Palou J, Xavier B, Laguna P, et al.: In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 1996, 47:482–484.

    Article  PubMed  CAS  Google Scholar 

  7. Lamm DL, Blumenstein BA, Crawford ED, et al.: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991, 325:1205–1209.

    Article  PubMed  CAS  Google Scholar 

  8. Guerin C: The history of BCG. In BCG Vaccine: Tuberculosis-Cancer, edn 2. Edited by Rosenthal SR. Littleton, MA: PSG Publishisng; 1980:35.

    Google Scholar 

  9. Pearl R: Cancer and tuberculosis. Proc Natl Acad Sci 1929, 9:97.

    Google Scholar 

  10. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976, 116:180–183.

    PubMed  CAS  Google Scholar 

  11. Lamm DL, Thor DE, Harris SC, et al.: Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980, 124:38–40.

    PubMed  CAS  Google Scholar 

  12. Becich MJ, Carroll S, Ratliff TL: Internalization of Bacille Calmette-Guérin by bladder tumor cells. J Urol 1991, 145:1316–1324.

    PubMed  CAS  Google Scholar 

  13. Ratliff TL, Hudson MA, Catalona WJ: Strategy for improving therapy of superficial bladder cancer. World J Urol 1991, 9:95–99.

    Article  Google Scholar 

  14. Morales A, Nickel JC. Immunotherapy of superficial bladder cancer with BCG. World J Urol 1986, 3:209–214.

    Article  Google Scholar 

  15. Garden RJ, Liu BCS, Redwood SM, et al.: Bacillus Calmette-Guérin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J Urol 1992, 148:900–905.

    PubMed  CAS  Google Scholar 

  16. Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL: Adverse impact of fibrin clot inhibitors on intravesical Bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 1990, 144:1362–1364.

    PubMed  CAS  Google Scholar 

  17. Ratliff TL, Gillen DP, Catalona WJ: Requirement of thymus dependent immune response for BCG mediated anitumor activity. J Urol 1987, 137:155–159.

    PubMed  CAS  Google Scholar 

  18. Davies M: Bacillus Calmette-Guérin as an antitumor agent. The interaction with cells of the mammalian immune system. Biochem Biophys Acta 1982, 651:143–147.

    PubMed  CAS  Google Scholar 

  19. Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986, 136:970–974.

    PubMed  CAS  Google Scholar 

  20. Morales A, Ottenhof PC: Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 1983, 52:667–670.

    Article  PubMed  CAS  Google Scholar 

  21. Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1992, 128:27.

    Google Scholar 

  22. Jansson OT, Morcos E, Brundin L, et al.: The role of nitric oxide in bacillus Calmette-Guerin mediated antitumour effects in human bladder cancer. Br J Cancer 1998, 78:588–592.

    PubMed  CAS  Google Scholar 

  23. Lamm DL: Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 1985,134:40–47.

    PubMed  CAS  Google Scholar 

  24. Herr HW, Pinsky CM, Whitmore WF Jr, et al.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985, 25:119–123.

    Article  PubMed  CAS  Google Scholar 

  25. Herr HW, Laudone VP, Badalament RA, et al.: Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988, 6:1450–1455.

    PubMed  CAS  Google Scholar 

  26. Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. In The Urologic Clinics of North America. Edited by Fair WR. Philadelphia: WB Saunders; 1991:525–528.

    Google Scholar 

  27. Pagano F, Bassi P, Milani C, et al.: Low dose BCG regimen in superficial bladder cancer therapy: is it effective? J Urol 1991, 146:32–35.

    PubMed  CAS  Google Scholar 

  28. Melekos MD, Chionis H, Pantazakos A, et al.: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993, 149:744–748.

    PubMed  CAS  Google Scholar 

  29. Krege S, Giani G, Meyer R, et al.: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996, 156:962–926.

    Article  PubMed  CAS  Google Scholar 

  30. Brake M, Loertzer H, Horsch R, Keller H: Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 2000, 55:673–678.

    Article  PubMed  CAS  Google Scholar 

  31. Coplen DE, Marcus MD, Myers JA, et al.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990, 144:652–657.

    PubMed  CAS  Google Scholar 

  32. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. In The Urologic Clinics of North America. Edited by Lamm DL. Philadelphia: WB Saunders; 1992:573–580.

    Google Scholar 

  33. De Jager R, Guinan P, Lamm D, et al.: Long term complete remission in bladder carcinoma in situ with intravesical Tice Bacillus Calmette Guerin—overview analysis of six pahse II clinical trials. Urology 1991, 38:507–514.

    Article  PubMed  Google Scholar 

  34. Akaza H, Hinotsu S, Aso Y, et al.: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995, 75:552–559.

    Article  PubMed  CAS  Google Scholar 

  35. Mungan NA, Witjes JA: Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol 1998, 82:213–223.

    PubMed  CAS  Google Scholar 

  36. Orsola A, Palou J, Xavier B, et al.: Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 1998, 33:457–463.

    Article  PubMed  CAS  Google Scholar 

  37. Klein EA, Rogatko A, Herr HW: Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 1992, 147:601–605.

    PubMed  CAS  Google Scholar 

  38. Rosenbaum RS, Park MC, Fleischmann J: Intravesical bacille Calmette-Guerin therapy for muscle invasive bladder cancer. Urology 1996, 47:208–211.

    Article  PubMed  CAS  Google Scholar 

  39. Lamm DL, DeHaven JI, Shriver J, Sarosdy MF: Percutaneous and intravesical prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol 1991, 145:738–740.

    PubMed  CAS  Google Scholar 

  40. D’Ancona CA, Netto Jr NR, Claro JA, Ikari O: Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol 1991, 145:498–501.

    PubMed  CAS  Google Scholar 

  41. Morales A, Ottenhof P, Emerson L: Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 1981, 125:649–651.

    PubMed  CAS  Google Scholar 

  42. Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al.: Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparision with other doses. Actas Urol Esp 1993, 17:239–242.

    Google Scholar 

  43. Kelley DR, Ratliff TL, Catalona WJ, et al.: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol 1985, 134:48–53.

    PubMed  CAS  Google Scholar 

  44. Witjes JA, Fransen MPH, van der Meijden APM, et al.: Use of maintenance intravesical Bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Urol Int 1993, 51:67–72.

    Article  PubMed  CAS  Google Scholar 

  45. Kavoussi LR, Torrence RJ, Gillen DP, et al.: Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 1988, 139:935–940.

    PubMed  CAS  Google Scholar 

  46. Palou J, Laguna P, Algaba F, et al.: High grade superficial transitional cell cercinoma of the bladder and/or CIS treatment with BCG: control vs maintenance treatment. Br J Urol 1997, 80(suppl):32.

    Google Scholar 

  47. Lamm DL, Blumenstein B, Sarsody M, et al.: Significant long-term patient benefits with BCG maintenance therapy:a South West Oncology Group study. J Urol 1997, 157:213.

    Article  Google Scholar 

  48. Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124–1129. A much awaited follow-up on the often quoted results previously only found in abstract form. This paper validates Lamm’s 6+3 protocol and shows a significant advantage of maintenance BCG therapy.

    Article  PubMed  CAS  Google Scholar 

  49. Lamm DL, van der Meijden APM, Morales A, et al.: Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992, 147:596–600.

    PubMed  CAS  Google Scholar 

  50. De Boer EC, Steerenberg PA, van der Meijden APM, et al.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 1992, 148:1577–1582.

    PubMed  Google Scholar 

  51. DeHaven JI, Traynelis C, Riggs DR, et al.: Antibiotic and steroid therapy of massive systemic Bacillus Calmette-Guérin toxicity. J Urol 1992, 147:738–742.

    PubMed  CAS  Google Scholar 

  52. Bohle A, Schuller J, Knipper A, Hofstetter A: Bacillus Calmette-Guerin treatment and vesicorenal reflux. Eur Urol 1990, 17:125–128.

    PubMed  CAS  Google Scholar 

  53. Borden EC, Groveman DS, Nasu T, et al.: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984, 132:800–803.

    PubMed  CAS  Google Scholar 

  54. Torti FM, Shortliffe LD, Williams RD, et al.: Alpha-Interferon in superficial bladder cancer: a northern California oncology group study. J Clin Oncol 1988, 6:476–483.

    PubMed  CAS  Google Scholar 

  55. Glashan R: A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol 1990, 144:658–661.

    PubMed  CAS  Google Scholar 

  56. Kalble T, Beer M, Mendoza E, et al.: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 1994, 33:133–137.

    PubMed  CAS  Google Scholar 

  57. Boccardo F, Cannata D, Rubagotti A, et al.: Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994, 12:7–13.

    PubMed  CAS  Google Scholar 

  58. Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al.: Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 1997, 50:529–535.

    Article  PubMed  CAS  Google Scholar 

  59. Rajala P, Liukkonen T, Raitanen M, et al.: Transurethral resection with perioperative instilation on interferonalpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—Finnbladder III. J Urol 1999, 161:1133–1135. A well-designed randomized trial with a large number of patients that shows a benefit for intravesical chemotherapy after TURBT but not for immunotherapy. This is in accordance with the mechanisms of action of both modalities.

    Article  PubMed  CAS  Google Scholar 

  60. Riggs DR, Tarry WF, DeHaven JI, et al.: Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 1992, 147:212–214.

    PubMed  CAS  Google Scholar 

  61. Stricker P, Pryor K, Nicholson T, et al.: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996, 48:957–961.

    Article  PubMed  CAS  Google Scholar 

  62. Bercovich E, Deriu M, Manferrari F, Irianni G: BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995, 67:257–260.

    PubMed  CAS  Google Scholar 

  63. Brown DH, Wagner TT, Bahnson RR: Interferons and bladder cancer. Urol Clin North Am 2000, 27:171–178. A comprehensive review of the role of interferons in bladder cancer.

    Article  PubMed  CAS  Google Scholar 

  64. Lamm DL, DeHaven JI, Riggs DR, et al.: Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Urol Res 1993, 21:33–37.

    Article  PubMed  CAS  Google Scholar 

  65. Jurincic CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988, 139:723–726.

    PubMed  CAS  Google Scholar 

  66. Lamm DL, Dehaven JI, Riggs DR: Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000, 37(suppl):41–44.

    Article  Google Scholar 

  67. Sardosy MF, Lowe BA, Schellhammer PF, et al.: Bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996, 48:21–27.

    Article  Google Scholar 

  68. Witjes WP, Konig M, Boeminghaus FP, et al.: Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 1999, 36:576–581.

    Article  PubMed  CAS  Google Scholar 

  69. Den OtterW, Dobrowolski Z, Bugajski A, et al.: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998, 159:1183–1186.

    Article  Google Scholar 

  70. Eto M, Harada M, Tamada K, et al.: Antitumor activity of interleukin-12 against murine bladder cancer. J Urol 2000, 163:1549–1552.

    Article  PubMed  CAS  Google Scholar 

  71. Clinton SK, Canto E, O’Donnell MA: Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 2000, 27:147–155.

    Article  PubMed  CAS  Google Scholar 

  72. Lau BHS, Woolley JL, Marsh CL, et al.: Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in the control of murine transitional cell carcinoma. J Urol 1986, 136:701.

    PubMed  CAS  Google Scholar 

  73. Riggs DR, DeHaven JI, Lamm DL: Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 1997, 79:1987.

    Article  PubMed  CAS  Google Scholar 

  74. Kamat AM, Lamm DL: Chemoprevention of urologic cancer. J Urol 1999, 161:1748–1760.

    Article  PubMed  CAS  Google Scholar 

  75. Lamm DL, Riggs DR, Shriver JS, et al.: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994, 151:21.

    PubMed  CAS  Google Scholar 

  76. Traynelis CL, Lamm DL: Current status of intravesical therapy for bladder cancer. In Urology Annual, vol 8. Edited by Rous SN. WW Norton; 1994:113–143.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Health Sciences Center, West Virginia University, PO Box 9251, 26506, Morgantown, WV, USA

    Ashish M. Kamat MD & Donald L. Lamm MD

Authors
  1. Ashish M. Kamat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald L. Lamm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamat, A.M., Lamm, D.L. Immunotherapy for bladder cancer. Curr Urol Rep 2, 62–69 (2001). https://doi.org/10.1007/s11934-001-0027-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-001-0027-7

Keywords

Search

Navigation